Title: Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin.
Journal: Trials20110101
Title: Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension.
Journal: Biochimica et biophysica acta20101201
Title: Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies.
Journal: Science translational medicine20101124
Title: Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies.
Journal: Science translational medicine20101124
Title: Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach.
Journal: Medical hypotheses20070101
Title: Ouabain-dependent signaling in caveolae as a novel therapeutic target for hypertension.
Journal: Cellular and molecular biology (Noisy-le-Grand, France)20061230
Title: Hypertension, Na+/Ca2+ exchanger, and Na+, K+-ATPase.
Journal: Kidney international20060601
Title: Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension.
Journal: American journal of physiology. Regulatory, integrative and comparative physiology20060301
Title: A new antihypertensive agent that antagonizes the prohypertensive effect of endogenous ouabain and adducin.
Journal: Cardiovascular & hematological agents in medicinal chemistry20060101
Title: Adducin and hypertension.
Journal: Pharmacogenomics20051001
Title: OASIS-HT: design of a pharmacogenomic dose-finding study.
Journal: Pharmacogenomics20051001
Title: PST 2238 as an antihypertensive compound that antagonizes the effect of endogenous cardiac glycosides.
Journal: Acta poloniae pharmaceutica20050101
Title: Ouabain antagonists as antihypertensive agents.
Journal: Current pharmaceutical design20050101
Title: Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238.
Journal: The Journal of biological chemistry20040806
Title: Antihypertensive compounds that modulate the Na-K pump.
Journal: Annals of the New York Academy of Sciences20030401
Title: Genes and hypertension.
Journal: Current pharmaceutical design20030101
Title: PST 2238: a new antihypertensive compound that modulates renal Na-K pump function without diuretic activity in Milan hypertensive rats.
Journal: Journal of cardiovascular pharmacology20021201
Title: Endogenous cardiotonic steroids.
Journal: Cellular and molecular biology (Noisy-le-Grand, France)20010301
Title: Quadri L, et al. 17 beta-(3-furyl)-5 beta-androstane-3 beta, 14 beta, 17 alpha-triol (PST 2238). A very potent antihypertensive agent with a novel mechanism of action. J Med Chem. 1997 May 23;40(11):1561-4.
Title: Ferrari P, et al. PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension. J Pharmacol Exp Ther. 1999 Mar;288(3):1074-83.
Title: Matthias Lingemann, et al. The alpha-1 subunit of the Na+,K+-ATPase (ATP1A1) is required for macropinocytic entry of respiratory syncytial virus (RSV) in human respiratory epithelial cells. PLoS Pathog. 2019 Aug 5;15(8):e1007963.
Title: Camilla F Wenceslau, et al. Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats: the role of Na+,K+-ATPase/cSRC pathway. J Hypertens. 2014 Mar;32(3):542-54.
